
Investment company buying stakes in undervalued micro-cap stocks and pushing for change to release value

Biotechnology investment arm of Access Industries backing private and public biopharma companies

Access Biotechnology is the life-sciences investment arm of Access Industries. It was set up in 2019 and puts money into companies developing therapies for conditions with high unmet need. The unit is led by Liam Ratcliffe, formerly head of worldwide clinical research and development at Pfizer.
Portfolio companies range from discovery-stage technology platforms to late-stage clinical programmes. Examples include firms working on iron metabolism disorders, inflammatory and allergic disease, immune disease, and inherited bleeding disorders.
Summary written by TrustList from the business's own published information, Oct 2026.
2 images - click to enlarge
Access Biotechnology is ranked on 3 TrustList rankings: #9 on 1, #36 on 1 and #40 on 1.
Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Access Biotechnology has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.
On 2 of these it sits behind Magnetic Ventures.
It is one of 2 here listing cloud and energy.
Of the 18 here, 3 also cover seed stage and 3 also cover partners; 11 also work in New York City and 9 also work in London.
It is one of 4 here listing energy and one of 5 here listing cloud.
Of the top 59 here, 10 also cover healthtech and 9 also cover series a; 16 also work in San Francisco and 12 also work in Hong Kong.
Behind Puma Private Equity, ahead of Coutts.
It is one of 3 here listing energy and one of 4 here listing cloud.
Of the top 58 here, 10 also cover artificial intelligence and 8 also cover biotech; 10 also work in Silicon Valley and 9 also work in Chicago.
As of 2026-11-16. Organic ranks only; sponsored placements are never ranks. How TrustList ranks
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Access Biotechnology.
Similar listings buyers compare against this one.

Investment company buying stakes in undervalued micro-cap stocks and pushing for change to release value

Capital and advisory firm for blockchain projects, part of Faculty Group

Technology investor backing fast-growing, high-margin companies in fintech and other large markets

Early-stage venture capital firm backing deep technology founders in Israel, Europe and the United States

Early-stage venture firm backing pre-seed and seed founders in Canada and the US

Investor in software-led teams aiming to automate large parts of the world across any sector or country

Asia Pacific venture capital firm investing in technology-related companies since 1990

Venture investor backing entrepreneurs who improve people's financial health
Everything here links back to the same verified catalogue. Pick your next stop.